Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation

Tom Ottoboni,1 Mary Rose Keller,2 Matt Cravets,3 Neil Clendeninn,4 Barry Quart5 1Pharmaceutical and Translational Sciences, Heron Therapeutics, Inc., San Diego, CA, USA; 2Clinical Operations, Heron Therapeutics, Inc., San Diego, CA, USA; 3Biometrics, Heron Therapeutics, Inc., San Diego, CA, USA; 4Cl...

Full description

Saved in:
Bibliographic Details
Main Authors: Ottoboni T (Author), Keller MR (Author), Cravets M (Author), Clendeninn N (Author), Quart B (Author)
Format: Book
Published: Dove Medical Press, 2018-03-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available